CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System ...
Platelet transfusion in neonates and children varies widely, with donor and processing factors linked to lower platelet increments and higher transfusion burden but not to mortality or length of stay.
Reports of unusual blood clots in the setting of low platelets associated with COVID-19 vaccines have brought attention to these tiny cell fragments tasked with preventing humans from fatally bleeding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results